Microbiology Services, NHS Blood and Transplant, London, UK
Infection and Immunity, University College London, London, UK.
Sex Transm Infect. 2022 Mar;98(2):132-135. doi: 10.1136/sextrans-2021-054981. Epub 2021 Mar 29.
Due to increased use of pre-exposure prohylaxis (PrEP) and its potential to affect HIV screening of blood donors, we undertook antiretroviral residual testing among HIV-negative male donors in England.
Residual plasma samples were obtainnd from 46 male donors confirmed positive for syphilis and 96 donors who were repeat reactive for HIV antibodies in screening but confirmed as HIV-negative by reference testing. These were tested for concentrations of tenofovir and emtricitabine by high-performance liquid chromatograhpy coupled with mass spectrometry.
We found evidence of pre-exposure or post-exposure prophylaxis (PrEP/PEP) use in three male blood donors confirmed positive for syphilis (3 out of 46 screened, 6.5%). Two were estimated to have taken PrEP/PEP within a day of donating, and the third within 2 days. Two were new donors, whereas one had donated previously but acquired syphilis infection after his last donation.
Our findings indicate that a small proportion of blood donors have not been disclosing PrEP/PEP use and therefore donating in non-compliance to donor eligibility criteria.
由于暴露前预防（PrEP）的使用增加及其可能影响献血者的 HIV 筛查，我们在英格兰对 HIV 阴性男性献血者进行了抗逆转录病毒残留检测。
从确诊梅毒阳性的 46 名男性献血者和 96 名在筛查中 HIV 抗体重复反应但经参考检测确认为 HIV 阴性的献血者中获得残余血浆样本。这些样本通过高效液相色谱-质谱联用技术检测 tenofovir 和 emtricitabine 的浓度。
我们在 3 名确诊梅毒阳性的男性献血者中发现了暴露前或暴露后预防（PrEP/PEP）用药的证据（46 名筛查者中 3 例，6.5%）。其中 2 人估计在献血前一天内服用了 PrEP/PEP，第 3 人在 2 天内服用了 PrEP/PEP。其中 2 人是新献血者，而 1 人以前曾献血，但在最后一次献血后感染了梅毒。
我们的发现表明，一小部分献血者没有披露 PrEP/PEP 的使用情况，因此不符合献血者资格标准。
